SNDX Latest Press Releases

-- November 4, 2026 --

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026 Globe Newswire 9:01 AM

Syndax Highlights Acceptance of 19 Revuforj (revumenib) and Niktimvo (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026 Globe Newswire 9:00 AM

-- November 3, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX Globe Newswire 5:50 PM

-- November 2, 2026 --

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:01 PM

Syndax Announces CFO Transition - Aaron A. Ondrey Appointed Chief Financial Officer Globe Newswire 4:01 PM

-- October 30, 2026 --

Syndax's Revuforj (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases Globe Newswire 9:01 AM

Syndax Announces Participation in November Investor Conferences Globe Newswire 7:00 AM

-- October 29, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX PRNewswire 10:00 AM

-- October 26, 2026 --

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026 Globe Newswire 7:00 AM

-- October 17, 2026 --

SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law Business Wire 9:22 PM

-- October 15, 2026 --

Syndax's Revuforj (revumenib) Named to TIME's Best Inventions of 2026 List Globe Newswire 4:01 PM

-- October 13, 2026 --

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) PRNewswire 10:18 PM

-- October 12, 2026 --

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis Globe Newswire 4:01 PM

-- October 2, 2026 --

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 4, 2026 --

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 1, 2026 --

Syndax Announces Participation in September Investor Conferences Globe Newswire 7:00 AM

-- August 5, 2026 --

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- August 4, 2026 --

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:01 PM

-- July 28, 2026 --

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 Globe Newswire 7:00 AM

-- July 14, 2026 --

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event Globe Newswire 8:00 AM

-- July 1, 2026 --

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- June 11, 2026 --

Syndax Showcases Revuforj (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 Globe Newswire 7:03 AM

Syndax Announces Publication of SAVE Data on Revuforj (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes